Pub Date : 2025-11-11DOI: 10.1038/s41582-025-01166-8
Ian Fyfe
Developmental trajectories and genetic architectures differ between inidividuals with autism who are diagnosed early or later in life, new research has shown.
新的研究表明，自闭症患者的发育轨迹和基因结构在早期和晚期诊断出自闭症的个体之间存在差异。
{"title":"Autism profiles differ with age of diagnosis","authors":"Ian Fyfe","doi":"10.1038/s41582-025-01166-8","DOIUrl":"10.1038/s41582-025-01166-8","url":null,"abstract":"Developmental trajectories and genetic architectures differ between inidividuals with autism who are diagnosed early or later in life, new research has shown.","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"21 12","pages":"668-668"},"PeriodicalIF":33.1,"publicationDate":"2025-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145491721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-11DOI: 10.1038/s41582-025-01168-6
Ian Fyfe
Serial analysis of glioblastoma tissue during treatment can help to reveal and monitor treatment responses, according to a new study.
根据一项新的研究，在治疗期间对胶质母细胞瘤组织进行连续分析可以帮助揭示和监测治疗反应。
{"title":"Glioblastoma biopsy reveals treatment response","authors":"Ian Fyfe","doi":"10.1038/s41582-025-01168-6","DOIUrl":"10.1038/s41582-025-01168-6","url":null,"abstract":"Serial analysis of glioblastoma tissue during treatment can help to reveal and monitor treatment responses, according to a new study.","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"21 12","pages":"668-668"},"PeriodicalIF":33.1,"publicationDate":"2025-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145492471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-03DOI: 10.1038/s41582-025-01154-y
Jorge J. Llibre-Guerra, Eric M. McDade, Suzanne E. Schindler, David B. Clifford, Charlene Supnet, Alireza Atri, Randall J. Bateman
Prevention of Alzheimer disease (AD) is a medical challenge owing to its complex pathogenesis, which involves amyloid-β (Aβ) and tau aggregation, neuroinflammation and progressive neurodegeneration. Development of disease-specific biomarkers has transformed our ability to detect AD pathology early, enabling more accurate diagnosis, monitoring and the development of targeted disease-modifying therapies. Consequently, primary and secondary prevention of AD have become feasible goals. In this Perspective, we examine current and emerging pharmacological strategies for the prevention of AD, particularly the use of existing anti-Aβ therapies and emerging anti-tau approaches, among people at risk of AD or in the earliest, presymptomatic stages of the disease. We highlight the key challenges in implementing prevention trials, discuss ongoing prevention trials and their implications, and consider the potential and challenges of translation into clinical practice. Implementation of preventative strategies, supported by biomarker-guided patient selection and innovative trial designs, has the potential to substantially delay or prevent the cognitive decline caused by AD. Success would fundamentally transform the AD therapeutic landscape, reducing the socioeconomic burden of dementia and preserving cognitive function in ageing populations worldwide. Advances in biomarkers, blood tests and disease-modifying therapies have created a credible path to clinical prevention of Alzheimer disease (AD). In this Perspective, the authors discuss promising approaches to the prevention of AD and highlight strategic gaps.
阿尔茨海默病（AD）的发病机制复杂，涉及淀粉样蛋白-β (a β)和tau蛋白聚集、神经炎症和进行性神经退行性变，因此预防AD是一项医学挑战。疾病特异性生物标志物的发展改变了我们早期发现阿尔茨海默病病理的能力，使更准确的诊断、监测和靶向疾病治疗的发展成为可能。因此，阿尔茨海默病的一级和二级预防已成为可行的目标。从这个角度来看，我们研究了当前和新兴的预防阿尔茨海默病的药理学策略，特别是在阿尔茨海默病风险人群或疾病早期症状前阶段使用现有的抗a β疗法和新兴的抗tau方法。我们强调了实施预防试验的关键挑战，讨论了正在进行的预防试验及其影响，并考虑了转化为临床实践的潜力和挑战。在生物标志物引导的患者选择和创新试验设计的支持下，实施预防策略有可能大大延缓或预防阿尔茨海默病引起的认知能力下降。成功将从根本上改变阿尔茨海默病的治疗前景，减少痴呆症的社会经济负担，并保持全球老年人口的认知功能。
{"title":"Towards pharmacological prevention of Alzheimer disease","authors":"Jorge J. Llibre-Guerra, Eric M. McDade, Suzanne E. Schindler, David B. Clifford, Charlene Supnet, Alireza Atri, Randall J. Bateman","doi":"10.1038/s41582-025-01154-y","DOIUrl":"10.1038/s41582-025-01154-y","url":null,"abstract":"Prevention of Alzheimer disease (AD) is a medical challenge owing to its complex pathogenesis, which involves amyloid-β (Aβ) and tau aggregation, neuroinflammation and progressive neurodegeneration. Development of disease-specific biomarkers has transformed our ability to detect AD pathology early, enabling more accurate diagnosis, monitoring and the development of targeted disease-modifying therapies. Consequently, primary and secondary prevention of AD have become feasible goals. In this Perspective, we examine current and emerging pharmacological strategies for the prevention of AD, particularly the use of existing anti-Aβ therapies and emerging anti-tau approaches, among people at risk of AD or in the earliest, presymptomatic stages of the disease. We highlight the key challenges in implementing prevention trials, discuss ongoing prevention trials and their implications, and consider the potential and challenges of translation into clinical practice. Implementation of preventative strategies, supported by biomarker-guided patient selection and innovative trial designs, has the potential to substantially delay or prevent the cognitive decline caused by AD. Success would fundamentally transform the AD therapeutic landscape, reducing the socioeconomic burden of dementia and preserving cognitive function in ageing populations worldwide. Advances in biomarkers, blood tests and disease-modifying therapies have created a credible path to clinical prevention of Alzheimer disease (AD). In this Perspective, the authors discuss promising approaches to the prevention of AD and highlight strategic gaps.","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"21 12","pages":"721-733"},"PeriodicalIF":33.1,"publicationDate":"2025-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145433941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-29DOI: 10.1038/s41582-025-01152-0
We are celebrating 20 years of Nature Reviews Neurology with our November 2025 issue. On reaching this milestone, we have refined and renewed our mission, and we continue to evolve the journal to support the translation of research into real-world benefits.
{"title":"Nature Reviews Neurology at 20 — on a mission to make a difference","authors":"","doi":"10.1038/s41582-025-01152-0","DOIUrl":"10.1038/s41582-025-01152-0","url":null,"abstract":"We are celebrating 20 years of Nature Reviews Neurology with our November 2025 issue. On reaching this milestone, we have refined and renewed our mission, and we continue to evolve the journal to support the translation of research into real-world benefits.","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"21 11","pages":"577-577"},"PeriodicalIF":33.1,"publicationDate":"2025-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.comhttps://www.nature.com/articles/s41582-025-01152-0.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145375379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-29DOI: 10.1038/s41582-025-01145-z
Lisa Kiani, Fernando Cendes
To mark the 20th anniversary of Nature Reviews Neurology, we have asked leaders of neurological societies across the world to reflect on progress over the past two decades and consider what the future holds for neurology in their region. Here, we speak to Fernando Cendes, Vice President of the Pan American Federation of Neurology.
{"title":"Neurology in 2025 — reflections from Latin America","authors":"Lisa Kiani, Fernando Cendes","doi":"10.1038/s41582-025-01145-z","DOIUrl":"10.1038/s41582-025-01145-z","url":null,"abstract":"To mark the 20th anniversary of Nature Reviews Neurology, we have asked leaders of neurological societies across the world to reflect on progress over the past two decades and consider what the future holds for neurology in their region. Here, we speak to Fernando Cendes, Vice President of the Pan American Federation of Neurology.","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"21 11","pages":"586-587"},"PeriodicalIF":33.1,"publicationDate":"2025-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145375342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-29DOI: 10.1038/s41582-025-01155-x
Ian Fyfe, Christopher Chen
To mark the 20th anniversary of Nature Reviews Neurology, we have asked leaders of neurological societies across the world to reflect on progress over the past two decades and consider what the future holds for neurology in their region. Here, we speak to Christopher Chen, President of the Asian and Oceanian Association of Neurology.
{"title":"Neurology in 2025 — reflections from Asia and Oceania","authors":"Ian Fyfe, Christopher Chen","doi":"10.1038/s41582-025-01155-x","DOIUrl":"10.1038/s41582-025-01155-x","url":null,"abstract":"To mark the 20th anniversary of Nature Reviews Neurology, we have asked leaders of neurological societies across the world to reflect on progress over the past two decades and consider what the future holds for neurology in their region. Here, we speak to Christopher Chen, President of the Asian and Oceanian Association of Neurology.","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"21 11","pages":"578-579"},"PeriodicalIF":33.1,"publicationDate":"2025-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145375376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-29DOI: 10.1038/s41582-025-01151-1
Lisa Kiani, Amina Gargouri, Riadh Gouider
To mark the 20th anniversary of Nature Reviews Neurology, we have asked leaders of neurological societies across the world to reflect on progress over the past two decades and consider what the future holds for neurology in their region. Here, we speak to Amina Gargouri and Riadh Gouider, President and Honorary President of the Pan-Arab Union of Neurological Societies.
{"title":"Neurology in 2025 — reflections from the Arab region","authors":"Lisa Kiani, Amina Gargouri, Riadh Gouider","doi":"10.1038/s41582-025-01151-1","DOIUrl":"10.1038/s41582-025-01151-1","url":null,"abstract":"To mark the 20th anniversary of Nature Reviews Neurology, we have asked leaders of neurological societies across the world to reflect on progress over the past two decades and consider what the future holds for neurology in their region. Here, we speak to Amina Gargouri and Riadh Gouider, President and Honorary President of the Pan-Arab Union of Neurological Societies.","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"21 11","pages":"580-581"},"PeriodicalIF":33.1,"publicationDate":"2025-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145375375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-29DOI: 10.1038/s41582-025-01147-x
Heather Wood, Lawrence Tucker, Augustina Charway-Felli
To mark the 20th anniversary of Nature Reviews Neurology, we have asked leaders of neurological societies across the world to reflect on progress over the past two decades and consider what the future holds for neurology in their region. Here, we speak to Lawrence Tucker and Augustina Charway-Felli, President and Past President, respectively, of the African Academy of Neurology.
{"title":"Neurology in 2025 — reflections from Africa","authors":"Heather Wood, Lawrence Tucker, Augustina Charway-Felli","doi":"10.1038/s41582-025-01147-x","DOIUrl":"10.1038/s41582-025-01147-x","url":null,"abstract":"To mark the 20th anniversary of Nature Reviews Neurology, we have asked leaders of neurological societies across the world to reflect on progress over the past two decades and consider what the future holds for neurology in their region. Here, we speak to Lawrence Tucker and Augustina Charway-Felli, President and Past President, respectively, of the African Academy of Neurology.","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"21 11","pages":"582-583"},"PeriodicalIF":33.1,"publicationDate":"2025-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145375378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-29DOI: 10.1038/s41582-025-01146-y
Heather Wood, Natalia S. Rost
To mark the 20th anniversary of Nature Reviews Neurology, we have asked leaders of neurological societies across the world to reflect on progress over the past two decades and consider what the future holds for neurology in their region. Here, we speak to Natalia S. Rost, President of the American Academy of Neurology.
为了纪念《自然评论神经病学》创刊20周年，我们邀请了世界各地神经学协会的领导人回顾过去20年的进展，并考虑他们所在地区神经学的未来。在这里，我们采访了美国神经病学学会主席Natalia S. Rost。
{"title":"Neurology in 2025 — reflections from the USA","authors":"Heather Wood, Natalia S. Rost","doi":"10.1038/s41582-025-01146-y","DOIUrl":"10.1038/s41582-025-01146-y","url":null,"abstract":"To mark the 20th anniversary of Nature Reviews Neurology, we have asked leaders of neurological societies across the world to reflect on progress over the past two decades and consider what the future holds for neurology in their region. Here, we speak to Natalia S. Rost, President of the American Academy of Neurology.","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"21 11","pages":"588-589"},"PeriodicalIF":33.1,"publicationDate":"2025-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145375377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-29DOI: 10.1038/s41582-025-01148-w
Ian Fyfe, Elena Moro
To mark the 20th anniversary of Nature Reviews Neurology, we have asked leaders of neurological societies across the world to reflect on progress over the past two decades and consider what the future holds for neurology in their region. Here, we speak to Elena Moro, President of the European Academy of Neurology.
{"title":"Neurology in 2025 – reflections from Europe","authors":"Ian Fyfe, Elena Moro","doi":"10.1038/s41582-025-01148-w","DOIUrl":"10.1038/s41582-025-01148-w","url":null,"abstract":"To mark the 20th anniversary of Nature Reviews Neurology, we have asked leaders of neurological societies across the world to reflect on progress over the past two decades and consider what the future holds for neurology in their region. Here, we speak to Elena Moro, President of the European Academy of Neurology.","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"21 11","pages":"584-585"},"PeriodicalIF":33.1,"publicationDate":"2025-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145375341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：